Tildrakizumab (EU: Ilumetri, U.S.: Ilumya) for the treatment of psoriasis

Introduction

Tildrakizumab (trade name EU: Ilumetri, U.S.: Ilumya) has been approved in Germany since September 2018 for the systemic treatment of moderate to severe plaque psoriasis in adults.

Psoriasis is a non-contagious inflammatory skin disease. The symptoms usually include clearly defined red patches (called "plaques"), scaly skin and often itching too. They come and go in bouts: The skin can get better on its own, but it may also suddenly get worse. Psoriasis is a chronic (long-lasting) condition that currently has no cure.

It is usually treated with creams or ointments. Treatment with UV light (phototherapy) is an option for people with severe psoriasis. There are also medications designed to slow down or stop the inflammatory process in different ways. They can either be taken as tablets or injected into the bloodstream. Treatment with drugs that have an effect on the entire body is called systemic treatment.

The antibody tildrakizumab is used to decrease the inflammation in the skin by inhibiting several chemical messengers.

Application

Tildrakizumab is available in ready-to-use syringes at a dose of 100 mg. It is injected into the skin (subcutaneously).

After the initial injection, the treatment is repeated one month later. Subsequent injections are given every three months. Patients can also inject themselves after being instructed how to do so by a doctor.

If there is no improvement after about 7 months, doctors usually recommend stopping the treatment.

Other treatments

For people with moderate to severe plaque psoriasis who are able to have systemic treatment for the first time, the drugs adalimumab, ciclosporin, ixekizumab, methotrexate or secukinumab are available. Phototherapy is also an option.

People who have already had systemic treatment – but it didn’t work well enough – can also use adalimumab, ixekizumab or secukinumab, or infliximab or ustekinumab, depending on what treatment was tried before.

Assessment

In 2019, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) wanted to look into the advantages and disadvantages of tildrakizumab compared with the standard treatments for moderate to severe plaque psoriasis in adults.

But the manufacturer didn’t provide any suitable data with which to do the assessment.

More information

This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, the G-BA passed a resolution on the added benefit of tildrakizumab (EU: Ilumetri, U.S.: Ilumya).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Tildrakizumab (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A18-78. February 13, 2019. (IQWiG reports; Volume 724).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Created on February 15, 2019
Next planned update: 2022

Authors/Publishers:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.